Annexon, Inc. (ANNX)
Largest Insider Buys in Sector
ANNX Stock Price History Chart
ANNX Stock Performance
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Insider Activity of Annexon, Inc.
Over the last 12 months, insiders at Annexon, Inc. have bought $1.15M and sold $381,570 worth of Annexon, Inc. stock.
On average, over the past 5 years, insiders at Annexon, Inc. have bought $14.78M and sold $1.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Satter Muneer A () — $6.05M. Carson William H. (director) — $139,517.
The last purchase of 3,200 shares for transaction amount of $17,056 was made by Carson William H. (director) on 2024‑12‑02.
List of Insider Buy and Sell Transactions, Annexon, Inc.
| 2024-12-02 | director | 3,200 0.003% | $5.33 | $17,056 | -5.60% | |||
| 2024-10-15 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,408 0.0062% | $7.41 | $40,073 | -22.75% | ||
| 2024-10-01 | director | 3,200 0.003% | $5.97 | $19,104 | +6.14% | |||
| 2024-09-19 | Sale | EVP & CHIEF INNOVATION OFFICER | 4,500 0.0043% | $7.10 | $31,950 | -8.68% | ||
| 2024-09-12 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.0048% | $6.16 | $33,880 | -1.49% | ||
| 2024-09-05 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.005% | $5.64 | $31,020 | +13.06% | ||
| 2024-09-03 | director | 3,200 0.0031% | $5.48 | $17,536 | +19.87% | |||
| 2024-08-29 | Sale | EVP & CHIEF INNOVATION OFFICER | 5,500 0.0052% | $5.95 | $32,725 | +7.17% | ||
| 2024-08-01 | director | 3,200 0.0031% | $6.24 | $19,968 | +0.16% | |||
| 2024-07-15 | Sale | EVP & CHIEF BUSINESS OFFICER | 784 0.0011% | $6.02 | $4,720 | 0.00% | ||
| 2024-07-15 | Sale | EVP & CHIEF FINANCIAL OFFICER | 1,104 0.0016% | $6.03 | $6,657 | 0.00% | ||
| 2024-07-15 | Sale | EVP & CHIEF INNOVATION OFFICER | 1,106 0.0016% | $6.02 | $6,658 | 0.00% | ||
| 2024-07-01 | director | 3,200 0.0038% | $5.00 | $16,000 | 0.00% | |||
| 2024-06-03 | director | 3,200 0.0037% | $4.83 | $15,459 | +30.57% | |||
| 2024-05-01 | director | 3,200 0.0035% | $4.68 | $14,982 | +22.11% | |||
| 2024-04-08 | director | 3,200 0.0036% | $6.07 | $19,411 | -5.62% | |||
| 2024-02-20 | Sale | EVP & CHIEF BUSINESS OFFICER | 1,951 0.0026% | $5.48 | $10,691 | +10.60% | ||
| 2024-02-20 | Sale | EVP & CHIEF FINANCIAL OFFICER | 2,593 0.0035% | $5.53 | $14,339 | +10.60% | ||
| 2024-02-20 | Sale | EVP & CHIEF INNOVATION OFFICER | 2,604 0.0035% | $5.51 | $14,348 | +10.60% | ||
| 2024-02-12 | Sale | PRESIDENT AND CEO | 5,782 0.0076% | $5.54 | $32,032 | +5.16% |
Insider Historical Profitability
| Satter Muneer A | 7406024 6.9479% | $4.54 | 3 | 0 | <0.0001% | |
| Love Douglas | PRESIDENT AND CEO | 196121 0.184% | $4.54 | 1 | 9 | +135.71% |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | 94622 0.0888% | $4.54 | 0 | 6 | |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | 86468 0.0811% | $4.54 | 1 | 9 | +33.07% |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER | 71365 0.067% | $4.54 | 0 | 13 | |
| Carson William H. | director | 25600 0.024% | $4.54 | 8 | 0 | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 5701926 5.3492% | $4.54 | 2 | 0 | +48.92% |
| Clarus Lifesciences III, L.P. | 10 percent owner | 2730635 2.5617% | $4.54 | 1 | 0 | +33.07% |
| Flynn James E | 10 percent owner | 808914 0.7589% | $4.54 | 1 | 0 | +33.07% |
| Keswani Sanjay | EVP & Chief Medical Officer | 0 0% | $4.54 | 0 | 1 |
Institutional Investor Ownership
| Fidelity Investments | $67.2M | 9.06 | 9.37M | -3.23% | -$2.24M | <0.01 | |
| Bain Capital Life Sciences Investors Llc | $62.4M | 8.41 | 8.7M | +7.96% | +$4.6M | 5.02 | |
| Alerce Investment Management L P | $53.1M | 7.16 | 7.41M | 0% | +$0 | 0.62 | |
| Bvf Inc Il | $50.19M | 6.76 | 7M | 0% | +$0 | 0.37 | |
| Redmile Group | $39.46M | 5.32 | 5.5M | 0% | +$0 | 0.4 | |
| Point72 Asset Management | $36.97M | 4.98 | 5.16M | New | +$36.97M | 0.05 | |
| BlackRock | $36.16M | 4.87 | 5.04M | +51.98% | +$12.37M | <0.01 | |
| Adage Capital Partners Gp L L C | $30.97M | 4.18 | 4.32M | -13.6% | -$4.88M | 0.06 | |
| The Vanguard Group | $26.87M | 3.62 | 3.75M | +96.38% | +$13.19M | <0.0001 | |
| Logos Global Management Lp | $21.87M | 2.95 | 3.05M | -38.38% | -$13.62M | 2.36 | |
| GMT Capital | $18.97M | 2.56 | 2.65M | -12.41% | -$2.69M | 0.77 | |
| Bellevue Group | $15.65M | 2.11 | 2.18M | New | +$15.65M | 0.24 | |
| Octagon Capital Advisors LP | $14.7M | 1.98 | 2.05M | 0% | +$0 | 0.08 | |
| Woodline Partners LP | $14.34M | 1.93 | 2M | +0.03% | +$4,366.53 | 0.12 | |
| Geode Capital Management | $10.25M | 1.38 | 1.43M | +55% | +$3.64M | <0.01 | |
| Ikarian Capital LLC | $10.07M | 1.36 | 1.41M | -46.98% | -$8.93M | 1.39 | |
| T. Rowe Price | $9.49M | 1.28 | 1.32M | +10,482.01% | +$9.4M | <0.01 | |
| Millennium Management LLC | $9.16M | 1.24 | 1.28M | +57.6% | +$3.35M | 0.01 | |
| State Street | $8.59M | 1.16 | 1.2M | +41.58% | +$2.52M | <0.0001 | |
| Polar Capital | $7.17M | 0.97 | 1M | New | +$7.17M | 0.04 | |
| JPMorgan Chase | $6.88M | 0.93 | 959,648 | +3,143.7% | +$6.67M | <0.01 | |
| Acadian Asset Management | $6.87M | 0.93 | 957,993 | +9.61% | +$601,899.10 | 0.02 | |
| Morgan Stanley | $6.45M | 0.87 | 899,513 | +368.35% | +$5.07M | <0.0001 | |
| Invesco | $5.66M | 0.76 | 789,044 | +3,524.12% | +$5.5M | <0.01 | |
| Kennedy Capital Management Inc | $5.55M | 0.75 | 774,698 | -27.98% | -$2.16M | 0.12 | |
| Massachusetts Financial Services Co Ma | $5.55M | 0.75 | 773,914 | -0.52% | -$29,067.18 | <0.01 | |
| Schonfeld Group | $5.46M | 0.74 | 761,600 | +4,380% | +$5.34M | 0.03 | |
| Renaissance Technologies | $4.81M | 0.65 | 671,200 | +38.62% | +$1.34M | 0.01 | |
| Deerfield Management | $4.19M | 0.56 | 583,913 | 0% | +$0 | 0.01 | |
| Goldman Sachs | $4.04M | 0.54 | 562,966 | +97.58% | +$1.99M | <0.01 | |
| Northern Trust | $3.98M | 0.54 | 555,566 | +51.27% | +$1.35M | <0.01 | |
| Caption Management Llc | $3.58M | 0.48 | 500,000 | New | +$3.58M | 0.11 | |
| Board Of Trustees Of The Leland Stanford Junior University | $3.46M | 0.47 | 482,550 | 0% | +$0 | 0.3 | |
| D. E. Shaw & Co. | $2.72M | 0.37 | 379,254 | New | +$2.72M | <0.01 | |
| Boothbay Fund Management LLC | $2.69M | 0.36 | 375,276 | -46.98% | -$2.38M | 0.09 | |
| Two Sigma | $2.68M | 0.36 | 373,448 | +1,304.84% | +$2.49M | <0.01 | |
| Parkman Healthcare Partners Llc | $2.49M | 0.34 | 346,687 | New | +$2.49M | 0.31 | |
| Dimensional Fund Advisors | $2.39M | 0.32 | 333,913 | +283.6% | +$1.77M | <0.01 | |
| ExodusPoint Capital Management, LP | $2.26M | 0.31 | 315,155 | -8.1% | -$199,241.14 | 0.03 | |
| Marshall Wace | $2.26M | 0.31 | 315,612 | New | +$2.26M | <0.01 | |
| Nuveen | $2.21M | 0.3 | 308,058 | +58.3% | +$813,508.62 | <0.01 | |
| Soleus Capital Management, L.P. | $2.1M | 0.28 | 292,400 | -43.27% | -$1.6M | 0.01 | |
| Driehaus Capital Management LLC | $0 | 0.25 | 258,314 | 0% | +$0 | <0.0001 | |
| Citadel Advisors LLC | $1.85M | 0.25 | 258,675 | -75.54% | -$5.73M | <0.01 | |
| Ubs Oconnor Llc | $1.78M | 0.24 | 248,277 | -64.17% | -$3.19M | 0.08 | |
| Jump Financial Llc | $1.51M | 0.2 | 210,200 | New | +$1.51M | 0.01 | |
| Two Sigma Advisers LP | $1.39M | 0.19 | 194,400 | +129.25% | +$785,832.00 | <0.01 | |
| Charles Schwab | $1.3M | 0.18 | 181,051 | +46.4% | +$411,436.22 | <0.0001 | |
| BNY Mellon | $1.3M | 0.18 | 180,616 | +34.51% | +$332,250.70 | <0.0001 | |
| Bridgeway Capital Management | $1.27M | 0.17 | 177,500 | -1.11% | -$14,340.00 | 0.02 |